Anaconda Biomed receives European patent for ischemic stroke treatment

Anaconda Biomed, a medical technology company developing next-generation thrombectomy systems, has announced that the European Patent Office has granted the company a European patent for "A Device and a Thrombectomy Apparatus for Extraction of Thrombus from a Blood Vessel." 

In addition, the US 11,771,446 B2 was also granted to the company on October 3, 2023, for a method to improve the efficacy of removing cerebral vascular thrombi.

The newly granted patents join a list of 17 issued patents for Anaconda Biomed, including “Thrombectomy Device and System For Extraction Of Vascular Thrombi From A Blood Vessel” in the United States with Patent No. US 11,013,523 B2, among other key territories such as recently granted Canada and South Korea, together with Japan, China, Brazil, Taiwan and Australia. The company’s growing patent portfolio demonstrates its dedication to innovation and unwavering mission to revolutionise stroke treatment worldwide.

Richard Ferrari, Anaconda Biomed chairperson, said: "Every year, approximately 15 million people globally suffer from stroke. With these recent achievements, we are one step closer to offering our neurovascular recanalization technology to effectively treat these patients, minimising death and disabilities, and improving the quality of life for patients and their families."